---

Cardiac Amyloidosis: Virtual On the Road in Houston 

Program Director: Mouaz Al-Mallah, MD, FASNC

Fee: ​Free for members, $75 for non-members, Join ASNC and Save
Credits: Earn 3.25* AMA PRA Category 1 Credits™​ or 3.25* ARRT Category A CE credits 

 

*Credits subject to change
 

Agenda     Time Central Time Title Speaker 8:30 am - 8:35 am  Welcome Mouaz Al-Mallah, MD 8:35 am - 9:00 am  ATTR Cardiac Amyloidosis: Clinical Presentation and Outcomes Juan C. Lopez-Mattei, MD 9:00 am - 9:20 am  The Role of Echocardiography and Cardiac MRI in Suspected Cardiac Amyloidosis Faisal Nabi, MD 9:20 am - 9:45 am  PYP Imaging: Diagnostic Accuracy and Pitfalls Brett Sperry, MD 9:45 am - 10:00 am  Cardiac PET in Suspected Cardiac Amyloidosis Mouaz Al-Mallah, MD 10:00 am - 10:20 am  Management of ATTR Amyloidosis Barry Trachtenberg, MD 10:20 am - 10:40 am  Panel Discussion   10:40 am - 11:00 am  Break   11:00 am - 11:45 am  Case Presentations Mohammad Chamsi Pasha, DO Ali Agha, MD Alpana Senapati, DO Moderator: Mouaz Al-Mallah, MD   Panel: Faisal Nabi, MD Mahwash Kassi, MD JOhn Mahmarian, MD Barry Trachtenberg, MD 11:45 am - Noon  Final Remarks Mouaz Al-Mallah, MD

 
This program is jointly sponsored by the American Society of Nuclear Cardiology and Houston Methodist.

 

Cardiac Amyloidosis: Virtual On the Road in South Florida 

Title: South Florida Cardiac Amyloid Symposium
Wake up and Look Around
Towards Early Recognition, Diagnosis and Treatment of Cardiac Amyloidosis
Saturday, Oct. 31
8:00 am to Noon (EDT)
Program Director: David Wolinsky, MD, MASNC

Fee: ​Free for members, $75 for non-members, Join ASNC and Save
Credits: Earn 3.25* AMA PRA Category 1 Credits™​ or 3.25* ARRT Category A CE credits  

---

Register for upcoming webinars and view our extensive archives and portfolio of online education available for CME/CE credits.

---

The Cardiac Amyloidosis: On the Road programs will:

• Address the knowledge, competence and performance gaps in disease epidemiology, pathophysiology, diagnosis and treatments for ATTR-CM. 
• Improve diagnosis across all patient populations, timely referral to amyloid experts, and knowledge of treatment options with the goal of improving outcomes of patients with ATTR-CM. 
• Enhance the understanding of the overlap of cardiac amyloidosis with other conditions leading to a misdiagnosis or delayed diagnosis.  
• Focus on the diagnostic algorithm, including the appropriate use of Tc-99m PYP, and the importance of image interpretation alongside other clinical findings. 
• Discuss the central role of Tc-99m PYP imaging and the protocols for acquisition, processing and interpretation to ensure understanding of the procedure and the data it provides.
   

Participants of these programs will be able to:

• Describe amyloidosis, including specific types, cardiac features and disease burden.
• Identify barriers to identification and diagnosis of patients suspected of ATTR.
• Recognize patients at risk for hereditary ATTR (hATTR) and wild-type ATTR (wtATTR).
• Summarize the diagnostic evaluation for cardiac amyloidosis including the differential diagnosis. 
• Provide details of Tc-99m PYP including imaging protocol, semi-quantitative and quantitative scoring, interpretation including identifying false positive and false negative studies, and components of an appropriate report. 
• Demonstrate understanding of current treatments for patients with ATTR-CM.

If you have any questions about registration, please contact info@asnc.org

These programs are supported by educational grants from Pfizer.
 

More Cardiac Amyloidosis Resources